X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LipoMedix's lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex injectable products.
Lead Product(s): Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area: Oncology Product Name: Promitil
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ForDoz
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2021
Details:
Fordoz will support LipoMedix to develop and manufacture Promitil in the United States. Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy.
Lead Product(s): Pegylated liposomal Mitomycin-c prodrug,Capecitabine
Therapeutic Area: Oncology Product Name: Promitil
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ForDoz
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2021
Details:
Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).
Lead Product(s): Promitil,Capecitabine,Bevacizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
